Q-omics provides the consensus-scored LRRC46 profile across patient tissues and cancer cell-line models. LRRC46 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRRC46 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, LRRC46 RNA expression shows 16,307 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, BLCA, and TGCT as cancer lineages where LRRC46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC46 survival associations across molecular data types. LRRC46 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC46 RNA expression–survival associations across cancer types. High LRRC46 expression shows unfavorable associations in KICH, ACC, LGG and KIRC, but favorable associations in UVM and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRRC46 RNA expression.
This table summarizes LRRC46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LRRC46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC46 shows lower tumor expression in LUSC and LUAD and higher tumor expression in BLCA, COAD, KIRP and STAD. The BLCA box plot shows higher LRRC46 RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with LRRC46 in patient tissues and cancer cell lines. In patient samples, LRRC46 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
